Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Gastrointestinal 1CNS 1

Conditions

Neoplasms 1Leukemia, Myeloid, Acute 1Glioma 1Cholangiocarcinoma 1

Interventions

venetoclax 74Specimen Handling 69Cyclophosphamide 61Cytarabine 52Biopsy 51fludarabine 45Azacitidine 38Rituximab 28fludarabine phosphate 22Methotrexate 22Vincristine 21Magnetic Resonance Spectroscopy 21blinatumomab 20Daunorubicin 20Prednisone 19Dexamethasone 17ibrutinib 16Whole-Body Irradiation 16Injections 16decitabine and cedazuridine drug combination 15Tacrolimus 14Mycophenolic Acid 14Melphalan 14Doxorubicin 14Busulfan 14obinutuzumab 13merphos 13acalabrutinib 13Mercaptopurine 13Granulocyte Colony-Stimulating Factor 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cytochrome P-450 CYP2B6 × Other hematologic neoplasm × 30 days × Clear all
NCT07486713 2026-06-05

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Rigel Pharmaceuticals

Phase 4 Recruiting
16 enrolled
CNSGastrointestinalOther hematologic neoplasm

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡